Roffman Miller Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$28.2M Buy
24,380
+1,091
+5% +$1.29M 1.45% 25
2026
Q2
$27.9M Buy
23,289
+3,240
+16% +$3.31M 1.46% 25
2026
Q1
$18.4M Buy
20,049
+898
+5% +$910K 1.06% 36
2025
Q4
$20.6M Buy
19,151
+2,629
+16% +$2.51M 1.12% 33
2025
Q3
$12.6M Buy
+16,522
New +$12.3M 0.71% 44
2020
Q3
– Sell
-4,484
Closed -$736K – 112
2020
Q2
$736K Buy
+4,484
New +$688K 0.07% 81

Other funds holding LLY

Roffman Miller Associates's LLY Position: Q3 2026 in Review

Roffman Miller Associates increased its Eli Lilly (LLY) stake by 4.7% in Q3 2026, buying an estimated $1.29M and bringing the position to 24,380 shares worth $28.2M. The position accounts for 1.45% of the portfolio, ranked #25.

Roffman Miller Associates first reported a position in LLY in Q2 2020 and has held it in 6 quarters since. 1,741 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Roffman Miller Associates held 24,380 shares of Eli Lilly worth $28.2M as of Q3 2026.
  • Roffman Miller Associates bought 1,091 Eli Lilly shares in Q3 2026, an estimated $1.29M.
  • Eli Lilly made up 1.45% of Roffman Miller Associates's portfolio in Q3 2026, its #25 holding.
  • Roffman Miller Associates first reported a position in Eli Lilly in Q2 2020 and has held it in 6 quarters since.
  • 1,741 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Roffman Miller Associates's 13F filing for Q3 2026, filed 19 Oct 2026.